Generic Medicine Info
May be taken with or without food.
Severe hypertension or coronary artery disease. Children <12 years. Concomitant or within 2 weeks of MAOI therapy.
Special Precautions
Patients with CV disease (e.g. hypertension, ischaemic heart disease), diabetes mellitus, increased intraocular pressure or angle-closure glaucoma, prostatic hyperplasia or urinary obstruction, seizure disorder, thyroid dysfunction. Mild to moderate renal and severe hepatic impairment. Children and elderly. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor relief of congestion, cardiac and CNS changes prior and during therapy.
Adverse Reactions
Significant: Severe skin reactions (e.g. acute generalised exanthematous pustulosis). Cardiac disorders: Tachycardia, arrhythmia, palpitation. Eye disorders: Angle-closure glaucoma. Gastrointestinal disorders: Dry mouth, nausea, vomiting. Nervous system disorders: Restlessness, tremors, headache, dizziness. Psychiatric disorders: Insomnia, sleep disturbances, anxiety, nervousness. Rarely, hallucinations (children). Renal and urinary disorders: Urinary retention. Skin and subcutaneous tissue disorders: Skin rashes. Vascular disorders: Hypertension.
Drug Interactions
May increase blood pressure with TCAs, other sympathomimetic agents (e.g. decongestants, appetite suppressants, amphetamine-like psychostimulants). May partially reverse the hypotensive effect of methyldopa, α- and β-blockers, bretylium, bethanidine, guanethidine, and debrisoquine. Elimination of pseudoephedrine may be enhanced by urinary acidifiers and decreased by urinary alkalinisers.
CIMS Class
Cough & Cold Preparations
ATC Classification
R01BA02 - pseudoephedrine ; Belongs to the class of systemic sympathomimetic preparations used as nasal decongestants.
Disclaimer: This information is independently developed by CIMS based on pseudoephedrine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in